Sanofi to cut US insulin prices after Eli Lilly and Novo Nordisk
A pharmacist holds a box of the drug Lantus SoloStar, manufactured by Sanofi Pharmaceutical, at a pharmacy in Provo, Utah, January 9, 2020.
George Frey | Reuters
Sanofi On Thursday, it announced plans to cut the U.S. price of its most popular insulin drug by 78% and cap monthly payouts at $35 for people who have private insurance from next year.
The French drugmaker is the latest major insulin maker to try to thwart government efforts to contain monthly costs by announcing its own steep price cuts for the life-saving hormone.
Eli Lily And Novo Nordisk made similar sweeping cuts earlier this month after years of political pressure and public outrage. The three companies control over 90% of the global insulin market.
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients over many years,” said Olivier Bogillot, Head of General Medicines at Sanofi in the United States. The change takes effect on January 1.
About 37 million people in the United States, or 11.3% of the country’s population, have diabetes, according to the Centers for Disease Control and Prevention.
cnbc-health care
